Nyxoah Receives $15 Million from European Investment Bank
Summary
Nyxoah SA announced it has received $15 million in proceeds from the second tranche of its loan facility with the European Investment Bank, bringing total capital raised in June 2026 to approximately $110 million. The non-dilutive debt funding complements the company's recent equity raise and will accelerate the commercial launch of Genio in the United States while supporting continued R&D investment and manufacturing scale-up.
Why it matters
Access to significant non-dilutive capital from a prestigious institutional lender like the EIB validates Nyxoah's technology and long-term commercial prospects. With approximately $110 million in total new capital secured in June alone, Nyxoah enters its next growth phase with a strengthened balance sheet that enables aggressive U.S. market expansion without diluting existing shareholders.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial